Ray G Thomas, Pelton Stephen I, Klugman Keith P, Strutton David R, Moore Matthew R
Division of Research, Kaiser Permanente Medical Care Program (Northern California Region), 2000 Broadway, Oakland, CA 94612, USA.
Vaccine. 2009 Nov 5;27(47):6483-94. doi: 10.1016/j.vaccine.2009.08.045. Epub 2009 Aug 29.
Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the United States since 2000 and data have indicated direct and indirect effects of the vaccine. We simulated the effects of PCV7 on children vaccinated during 2000-2006, incorporating direct and indirect effects on incidence of invasive pneumococcal disease (IPD), hospitalized pneumonia and otitis media. Before accounting for indirect effects, PCV7 cost $201,000 per life-year saved. After incorporating indirect effects on IPD, cost per life-year saved was $10,400. The presence of modest additional indirect effects against hospitalized pneumonia and otitis media in children may have resulted in overall cost savings.
七价肺炎球菌结合疫苗（PCV7）自2000年起在美国常规使用，数据显示了该疫苗的直接和间接效果。我们模拟了PCV7对2000 - 2006年期间接种疫苗儿童的影响，纳入了对侵袭性肺炎球菌疾病（IPD）、住院肺炎和中耳炎发病率的直接和间接影响。在考虑间接影响之前，PCV7每挽救一个生命年的成本为201,000美元。纳入对IPD的间接影响后，每挽救一个生命年的成本为10,400美元。儿童中对住院肺炎和中耳炎存在适度的额外间接影响可能导致了总体成本节约。
